Device allows UTI diagnosis after single patient visit, Pg12

Key Highlights:

• A new point-of-care platform called iPRISM has been developed to diagnose urinary tract infections (UTIs).
• iPRISM demonstrated 81% specificity and 82% sensitivity in screening for UTIs within 75 minutes during a double-blind clinical study.
• The platform accurately classified 100% of samples exposed to gentamicin in 30 minutes and identified ciprofloxacin resistance in 90 minutes.

Detailed Insights:

• UTIs are common infections, and rapid diagnosis is crucial for effective treatment and to combat antimicrobial resistance.
• iPRISM's speed allows for immediate treatment decisions, reducing the need for follow-up appointments and improving patient care.
• The platform supports antibiotic stewardship by enabling doctors to prescribe targeted antibiotics based on susceptibility testing results.

Scientific/Technical Concepts Involved:

• Specificity: The ability of a test to correctly identify those without the disease.
• Sensitivity: The ability of a test to correctly identify those with the disease.
• Antibiotic Stewardship: Efforts to reduce the overuse and misuse of antibiotics to combat antimicrobial resistance.

iPRISM